Efficacy and safety of mometasone furoate nasal spray in nasal polyposis

Change in bilateral polyp grade score from baseline to the endpoint. LS means and pairwise comparison P values were obtained from ANCOVA, with treatment, baseline asthma status, site effects, and baseline bilateral polyp grade score. Endpoint was defined as the last nonmissing reading for the subject. Baseline bilateral polyp grade scores were 4.21, 4.27, and 4.25 in the MFNS 200 μg QD, MFNS 200 μg BID, and placebo groups, respectively.

Change from baseline in congestion/obstruction score during the treatment period. LS means and pairwise comparison P values were obtained from ANOVA with treatment, baseline asthma status, and site effects. Baseline congestion/obstruction scores were 2.29, 2.35, and 2.28 in the MFNS 200 μg QD, MFNS 200 μg BID, and placebo groups, respectively.

Change from baseline in individual symptom scores (loss of smell, anterior rhinorrhea, and postnasal drip) at month 1 of treatment (A) and month 4 of treatment (B). LS means and pairwise comparison P values were obtained from ANOVA with treatment, baseline asthma status, and site effects. Baseline individual symptom scores were 2.27, 2.14, and 2.32 for loss of smell, 1.66, 1.62, and 1.58 for anterior rhinorrhea, and 1.55, 1.43, and 1.48 for postnasal drip in the MFNS 200 μg QD, MFNS 200 μg BID, and placebo groups, respectively.

Change from baseline in PNIF during the treatment period. LS means and pairwise comparison P values were obtained from ANOVA with treatment, baseline asthma status, and site effects. Baseline PNIF rates were 87.6 L/min, 92.7 L/min, and 83.9 L/min in the MFNS 200 μg QD, MFNS 200 μg BID, and placebo groups, respectively.